A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy
Authors:
Open Access
- 31 August 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 31 (9) , 1190-1203
Abstract
This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy. Eligible adults (18–65 years) were assigned to antidepressant monotherapy (escitalopram or venlafaxine extended-release) plus lisdexamfetamine dimesylate-matching placebo during an eight-week single-blind lead-in phase. Participants meeting randomization criteria were randomized (1:1:1:1:1) to eight weeks of lisdexamfetamine dimesylate (10, 30, 50, or 70 mg) or placebo while maintaining antidepressant therapy. Dose-responses for changes from augmentation baseline to week 16/early termination for Montgomery-Åsberg Depression Rating Scale total score (primary efficacy endpoint) and vital signs (systolic and diastolic blood pressure and pulse) were assessed using multiple comparisons procedures with modeling. For Montgomery-Åsberg Depression Rating Scale total score change, no significant dose-responses were observed for any candidate dose-response curve (all p>0.10). In the dose-response evaluable population, least squares mean (90% confidence interval) treatment differences versus placebo for Montgomery-Åsberg Depression Rating Scale total score change at week 16 were −1.4 (−3.9, 1.2), 0.1 (−2.5, 2.7), −0.7 (−3.4, 2.0), and −0.9 (−3.5, 1.6) with 10, 30, 50, and 70 mg lisdexamfetamine dimesylate, respectively. For all vital sign parameters, lisdexamfetamine dimesylate exhibited significant dose-responses for all candidate dose-response curves (all p<0.10), with increases observed as lisdexamfetamine dimesylate dose increased; a linear relationship provided the best fit. Mean±standard deviation changes from augmentation baseline for systolic and diastolic blood pressure and pulse at week 16/early termination were −0.7±9.90 and −0.3±7.24 mm Hg and 0.2±10.57 bpm with placebo and were 1.9±9.47 and 0.8±7.40 mm Hg and 3.6±9.74 bpm with lisdexamfetamine dimesylate (all doses combined). The safety and tolerability profile of lisdexamfetamine dimesylate was consistent with previous studies. Lisdexamfetamine dimesylate augmentation did not provide benefit over placebo in adults with inadequate responses to antidepressant monotherapy based on the assessed efficacy measures.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and Tolerability of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder in AdultsCNS Drugs, 2011
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisThe Lancet, 2009
- Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDDEuropean Neuropsychopharmacology, 2009
- Psychostimulants for depressionCochrane Database of Systematic Reviews, 2008
- Osmotic-Release Oral System Methylphenidate Augmentation of Antidepressant Monotherapy in Major Depressive DisorderThe Journal of Clinical Psychiatry, 2008
- Modafinil Augmentation of Selective Serotonin Reuptake Inhibitor Therapy in MDD Partial Responders with Persistent Fatigue and SleepinessAnnals of Clinical Psychiatry, 2007
- The Role of Dopamine in the Pathophysiology of DepressionArchives of General Psychiatry, 2007
- Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical PracticeAmerican Journal of Psychiatry, 2006
- US Valuation of the EQ-5D Health StatesMedical Care, 2005
- Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability ScaleThe International Journal of Psychiatry in Medicine, 1997